September 28, 2015 – Caldwell Partners has placed Angad Singh as chief technology officer and Kerstin Schultz as president and chief operating officer of BrainScope Company, Inc., a privately held neurotechnology company.
Michael T. Kelly, a partner in Caldwell’s life sciences practice, led the assignment. Mr. Kelly specializes in recruiting at the CEO, COO, CFO and board of director level, as well as for senior-level operations and staff positions ranging from start-up ventures to established Fortune 500 firms in the medical devices industry.
Mr. Singh has 18 years of experience developing and commercializing complex high-tech products, scaling-up operations, and improving product quality and profitability. Previously, he was VP operations and engineering / senior director operations of medical device company CardioMEMS.
Ms. Schultz is a 25-year healthcare industry veteran, where she most recently held the position of vice president of global project management at Allergan. Prior to that, she held a number of positions at Baxter Healthcare, including VP of portfolio and project management for the IV Therapy business, VP of strategy for the global parenteral nutrition business, and VP of strategy and R&D portfolio management. Before joining Baxter, Ms. Schultz was a management consultant with A.T. Kearney’s pharmaceutical and healthcare practice.
“These additions to our leadership team will help us build upon the positive momentum that we have established over the last several years,” said Michael Singer, chief executive officer of BrainScope. “We are ready to take the next step forward by adding substantial depth and expertise to our management team as we look to commercialize and sell our products in the near future.”
Caldwell Partners’ life sciences & healthcare practice has executed hundreds of recruitment assignments for a wide spectrum of organizations serving the community, academic and business sectors. Darin DeWitt serves as leader of the practice. Over the past year, Caldwell Partners has recruited the CEO for Surgical Specialties Corporation, filled a board position for therapeutic target discovery company AbVitro, Inc., and placed the chief medical officer of biopharmaceutical company MannKind Corporation.
Contributed by Dale M. Zupsansky, Managing Editor, Hunt Scanlon Media